The aryl hydrocarbon receptor ligand ITE inhibits TGFβ1-induced human myofibroblast differentiation

American Journal of Pathology

Volumn 178, Issue 4, 2011, Pages 1556-1567

  Lehmann, Geniece M ^a,c   Xi, Xia ^b   Kulkarni, Ajit A ^b   Olsen, Keith C ^b   Pollock, Stephen J ^a   Baglole, Carolyn J ^a,d   Gupta, Shikha ^a   Casey, Ann E ^a   Huxlin, Krystel R ^b   Sime, Patricia J ^a,b   Feldon, Steven E ^b   Phipps, Richard P ^a,b  

^a UNIVERSITY OF ROCHESTER   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 (1' H INDOLE 3' CARBONYL)THIAZOLE 4 CARBOXYLIC ACID METHYL ESTER; 2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; AROMATIC HYDROCARBON RECEPTOR; ITE; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL DIFFERENTIATION; CELL TRANSPORT; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOUSE; MYOFIBROBLAST; MYOFIBROBLAST DIFFERENTIATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION;

EID: 79953647514     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2010.12.025     Document Type: Article

References (58)

1. Ferguson MW, O'Kane S: Scar-free healing: from embryonic mechanisms to adult therapeutic intervention. Philos Trans R Soc Lond B Biol Sci 2004, 359:839-850 (Pubitemid 38673751)
2. Hantash BM, Zhao L, Knowles JA, Lorenz HP: Adult and fetal wound healing. Front Biosci 2008, 13:51-61 (Pubitemid 351594762)
3. Phan SH: The myofibroblast in pulmonary fibrosis. Chest 2002, 122:286S-289S
4. White ES, Lazar MH, Thannickal VJ: Pathogenetic mechanisms in usual interstitial pneumonia/idiopathic pulmonary fibrosis. J Pathol 2003, 201:343-354 (Pubitemid 37408254)
5. Ferguson HE, Kulkarni A, Lehmann GM, Garcia-Bates TM, Thatcher TH, Huxlin KR, Phipps RP, Sime PJ: Electrophilic peroxisome proliferator activated receptor-{gamma} (PPAR{gamma}) ligands have potent anti-fibrotic effects in human lung fibroblasts. Am J Respir Cell Mol Biol 2009, 41:722-730
6. Selman M, Thannickal VJ, Pardo A, Zisman DA, Martinez FJ, Lynch JP, 3rd: Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches. Drugs 2004, 64:405-430 (Pubitemid 38337436)
7. Zhang HY, Phan SH: Inhibition of myofibroblast apoptosis by transforming growth factor beta(1). Am J Respir Cell Mol Biol 1999, 21:658-665
8. Han R, Smith TJ: T helper type 1 and type 2 cytokines exert divergent influence on the induction of prostaglandin E2 and hyaluronan synthesis by interleukin-1beta in orbital fibroblasts: implications for the pathogenesis of thyroid-associated ophthalmopathy. Endocrinology 2006, 147:13-19 (Pubitemid 43004256)
9. Feldon SE, O'Loughlin CW, Ray DM, Landskroner-Eiger S, Seweryniak KE, Phipps RP: Activated human T lymphocytes express cyclooxygenase-2 and produce proadipogenic prostaglandins that drive human orbital fibroblast differentiation to adipocytes. Am J Pathol 2006, 169:1183-1193 (Pubitemid 351194355)
10. Feldon SE, Park DJ, O'Loughlin CW, Nguyen VT, Landskroner-Eiger S, Chang D, Thatcher TH, Phipps RP: Autologous T-lymphocytes stimulate proliferation of orbital fibroblasts derived from patients with Graves' ophthalmopathy. Invest Ophthalmol Vis Sci 2005, 46:3913-3921 (Pubitemid 44264589)
11. Kahaly G, Forster G, Hansen C: Glycosaminoglycans in thyroid eye disease. Thyroid 1998, 8:429-432 (Pubitemid 28252428)
12. Burgess HA, Daugherty LE, Thatcher TH, Lakatos HF, Ray DM, Redonnet M, Phipps RP, Sime PJ: PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2005, 288:L1146-1153
13. Sime PJ, O'Reilly KM: Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment. Clin Immunol 2001, 99:308-319
14. Carrington LM, Albon J, Anderson I, Kamma C, Boulton M: Differential regulation of key stages in early corneal wound healing by TGF-beta isoforms and their inhibitors. Invest Ophthalmol Vis Sci 2006, 47:1886-1894 (Pubitemid 46768268)
15. Meltzer EB, Noble PW: Idiopathic pulmonary fibrosis. Orphanet J Rare Dis 2008, 3:8
16. Lehmann GM, Feldon SE, Smith TJ, Phipps RP: Immune mechanisms in thyroid eye disease. Thyroid 2008, 18:959-965
17. Lehmann GM, Garcia-Bates TM, Smith TJ, Feldon SE, Phipps RP: Regulation of lymphocyte function by PPARgamma: relevance to thyroid eye disease-related inflammation. PPAR Res 2008, 2008:895-901
18. Border WA, Noble NA: Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994, 331:1286-1292 (Pubitemid 24333194)
19. Gomez-Duran A, Carvajal-Gonzalez JM, Mulero-Navarro S, Santiago-Josefat B, Puga A, Fernandez-Salguero PM: Fitting a xenobiotic receptor into cell homeostasis: how the dioxin receptor interacts with TGFbeta signaling. Biochem Pharmacol 2009, 77:700-712
20. Massague J, Gomis RR: The logic of TGFbeta signaling. FEBS Lett 2006, 580:2811-2820
21. Haarmann-Stemmann T, Bothe H, Abel J: Growth factors, cytokines and their receptors as downstream targets of arylhydrocarbon receptor (AhR) signaling pathways. Biochem Pharmacol 2009, 77:508-520
22. Henry EC, Bemis JC, Henry O, Kende AS, Gasiewicz TA: A potential endogenous ligand for the aryl hydrocarbon receptor has potent agonist activity in vitro and in vivo. Arch Biochem Biophys 2006, 450:67-77 (Pubitemid 43782737)
23. Fernandez-Salguero P, Pineau T, Hilbert DM, McPhail T, Lee SS, Kimura S, Nebert DW, Rudikoff S, Ward JM, Gonzalez FJ: Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor. Science 1995, 268:722-726
24. Corchero J, Martin-Partido G, Dallas SL, Fernandez-Salguero PM: Liver portal fibrosis in dioxin receptor-null mice that overexpress the latent transforming growth factor-beta-binding protein-1. Int J Exp Pathol 2004, 85:295-302 (Pubitemid 39319161)
25. Peterson TC, Hodgson P, Fernandez-Salguero P, Neumeister M, Gonzalez FJ: Hepatic fibrosis and cytochrome P450: experimental models of fibrosis compared with AHR knockout mice. Hepatol Res 2000, 17:112-125 (Pubitemid 30175936)
26. Barouki R, Coumoul X, Fernandez-Salguero PM: The aryl hydrocarbon receptor, more than a xenobiotic-interacting protein. FEBS Lett 2007, 581:3608-3615 (Pubitemid 47080995)
27. Song J, Clagett-Dame M, Peterson RE, Hahn ME, Westler WM, Sicinski RR, DeLuca HF: A ligand for the aryl hydrocarbon receptor isolated from lung. Proc Natl Acad Sci USA 2002, 99:14694-14699 (Pubitemid 35334546)
28. Bittinger MA, Nguyen LP, Bradfield CA: Aspartate aminotransferase generates proagonists of the aryl hydrocarbon receptor. Mol Pharmacol 2003, 64:550-556 (Pubitemid 37048557)
29. Adachi J, Mori Y, Matsui S, Takigami H, Fujino J, Kitagawa H, Miller CA, 3rd, Kato T, Saeki K, Matsuda T: Indirubin and indigo are potent aryl hydrocarbon receptor ligands present in human urine. J Biol Chem 2001, 276:31475-31478
30. Savouret JF, Antenos M, Quesne M, Xu J, Milgrom E, Casper RF: 7-Ketocholesterol is an endogenous modulator for the arylhydrocarbon receptor. J Biol Chem 2001, 276:3054-3059
31. Schaldach CM, Riby J, Bjeldanes LF: Lipoxin A4: a new class of ligand for the Ah receptor. Biochemistry 1999, 38:7594-7600
32. Sinal CJ, Bend JR: Aryl hydrocarbon receptor-dependent induction of cyp1a1 by bilirubin in mouse hepatoma hepa 1c1c7 cells. Mol Pharmacol 1997, 52:590-599 (Pubitemid 27443980)
33. Whitlock JP, Jr: Induction of cytochrome P4501A1, Annu Rev Pharmacol Toxicol 1999, 39:103-125
34. Fries KM, Sempowski GD, Gaspari AA, Blieden T, Looney RJ, Phipps RP: CD40 expression by human fibroblasts. Clin Immunol Immunopathol 1995, 77:42-51
35. Baglole CJ, Reddy SY, Pollock SJ, Feldon SE, Sime PJ, Smith TJ, Phipps RP: Isolation and phenotypic characterization of lung fibroblasts. Methods Mol Med 2005, 117:115-127
36. Mikami F, Lim JH, Ishinaga H, Ha UH, Gu H, Koga T, Jono H, Kai H, Li JD: The transforming growth factor-beta-Smad3/4 signaling pathway acts as a positive regulator for TLR2 induction by bacteria via a dual mechanism involving functional cooperation with NF-kappaB and MAPK phosphatase 1-dependent negative cross-talk with p38 MAPK. J Biol Chem 2006, 281:22397-22408 (Pubitemid 44181942)
37. Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB: Myofibroblasts. I. Paracrine cells important in health and disease. Am J Physiol Cell Physiol 1999, 277:C1-C19
38. Fries KM, Blieden T, Looney RJ, Sempowski GD, Silvera MR, Willis RA, Phipps RP: Evidence of fibroblast heterogeneity and the role of fibroblast subpopulations in fibrosis. Clin Immunol Immunopathol 1994, 72:283-292 (Pubitemid 24275206)
39. Leask A: Towards an anti-fibrotic therapy for scleroderma: targeting myofibroblast differentiation and recruitment. Fibrogenesis Tissue Repair 2010, 3:8
40. Kim G, Jun JB, Elkon KB: Necessary role of phosphatidylinositol 3-kinase in transforming growth factor β-mediated activation of Akt in normal and rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2002, 46:1504-1511 (Pubitemid 34620196)
41. Yakymovych I, Souchelnytskyi S: Regulation of Smad Function by Phosphorylation. Edited by Ten Dijke P, Heldin CH. Dordrecht, Springer, 2006, pp 235-252
42. Shi Y, Massague J: Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003, 113:685-700 (Pubitemid 36724933)
43. Wicks SJ, Lui S, Abdel-Wahab N, Mason RM, Chantry A: Inactivation of smad-transforming growth factor beta signaling by Ca(2+)-calmodulin-dependent protein kinase II. Mol Cell Biol 2000, 20:8103-8111
44. Kretzschmar M, Doody J, Timokhina I, Massague J: A mechanism of repression of TGFbeta/ Smad signaling by oncogenic Ras. Genes Dev 1999, 13:804-816 (Pubitemid 29169840)
45. McCormick LL, Zhang Y, Tootell E, Gilliam AC: Anti-TGF-{beta} treatment prevents skin and lung fibrosis in murine sclerodermatous graftversus- host disease: a model for human scleroderma. J Immunol 1999, 163:5693-5699
46. Denis M: Neutralization of transforming growth factor-beta 1 in a mouse model of immune-induced lung fibrosis. Immunology 1994, 82:584-590
47. Giri SN, Hyde DM, Hollinger MA: Effect of antibody to transforming growth factor beta on bleomycin induced accumulation of lung collagen in mice. Thorax 1993, 48:959-966 (Pubitemid 23319618)
48. Bonniaud P, Margetts PJ, Kolb M, Schroeder JA, Kapoun AM, Damm D, Murphy A, Chakravarty S, Dugar S, Higgins L, Protter AA, Gauldie J: Progressive transforming growth factor {beta}1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor. Am J Respir Crit Care Med 2005, 171:889-898 (Pubitemid 40562720)
49. Nakao A, Fujii M, Matsumura R, Kumano K, Saito Y, Miyazono K, Iwamoto I: Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J Clin Invest 1999, 104:5-11 (Pubitemid 29534339)
50. Kolb M, Margetts PJ, Galt T, Sime PJ, Xing Z, Schmidt M, Gauldie J: Transient transgene expression of decorin in the lung reduces the fibrotic response to bleomycin. Am J Respir Crit Care Med 2001, 163:770-777 (Pubitemid 32230842)
51. Jester JV, Barry-Lane PA, Petroll WM, Olsen DR, Cavanagh HD: Inhibition of corneal fibrosis by topical application of blocking antibodies to TGFβ in the rabbit. Cornea 1997, 16:177-187 (Pubitemid 27131581)
52. Møller-Pedersen T, Cavanagh HD, Petroll WM, Jester JV: Neutralizing antibody to TGFbeta modulates stromal fibrosis but not regression of photoablative effect following PRK. Curr Eye Res 1998, 17:736-747 (Pubitemid 28367786)
53. Buhren J, Nagy L, Swanton JN, Kenner S, MacRae S, Phipps RP, Huxlin KR: Optical effects of anti-TGFbeta treatment after photorefractive keratectomy in a cat model. Invest Ophthalmol Vis Sci 2009, 50:634-643
54. Ask K, Martin GE, Kolb M, Gauldie J: Targeting genes for treatment in idiopathic pulmonary fibrosis: challenges and opportunities, promises and pitfalls. Proc Am Thorac Soc 2006, 3:389-393 (Pubitemid 43845418)
55. Fernandez-Salguero PM, Hilbert DM, Rudikoff S, Ward JM, Gonzalez FJ: Aryl-hydrocarbon receptor-deficient mice are resistant to 2,3,7,8- tetrachlorodibenzo-p-dioxin-induced toxicity. Toxicol Appl Pharmacol 1996, 140:173-179
56. Mimura J, Fujii-Kuriyama Y: Functional role of AhR in the expression of toxic effects by TCDD. Biochim Biophys Acta 2003, 1619:263-268 (Pubitemid 36160604)
57. Shimizu Y, Nakatsuru Y, Ichinose M, Takahashi Y, Kume H, Mimura J, Fujii-Kuriyama Y, Ishikawa T: Benzo[a]pyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor. Proc Natl Acad Sci USA 2000, 97:779-782 (Pubitemid 30070386)
58. Henry EC, Welle SL, Gasiewicz TA: TCDD and a putative endogenous AhR ligand, ITE, elicit the same immediate changes in gene expression in mouse lung fibroblasts. Toxicol Sci 2010, 114:90-100